XML Financial LLC Decreases Stock Holdings in Pfizer Inc. $PFE

XML Financial LLC reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 15.4% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 99,422 shares of the biopharmaceutical company’s stock after selling 18,053 shares during the period. XML Financial LLC’s holdings in Pfizer were worth $2,394,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of PFE. BlackRock Inc. raised its position in Pfizer by 6.3% during the 2nd quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock valued at $12,754,464,000 after purchasing an additional 31,412,883 shares during the last quarter. State Street Corp grew its position in shares of Pfizer by 0.5% in the 4th quarter. State Street Corp now owns 300,445,164 shares of the biopharmaceutical company’s stock worth $7,481,085,000 after buying an additional 1,357,756 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Pfizer by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 130,192,081 shares of the biopharmaceutical company’s stock valued at $3,235,642,000 after buying an additional 1,184,728 shares during the period. Morgan Stanley increased its stake in shares of Pfizer by 19.2% during the fourth quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock valued at $2,218,929,000 after buying an additional 14,342,946 shares during the period. Finally, Norges Bank bought a new position in shares of Pfizer during the fourth quarter valued at approximately $1,830,986,000. 68.36% of the stock is owned by institutional investors.

Pfizer Price Performance

Shares of PFE stock opened at $28.57 on Wednesday. The business’s fifty day moving average is $25.69 and its 200 day moving average is $26.31. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. The stock has a market cap of $162.84 billion, a price-to-earnings ratio of 37.59 and a beta of 0.34. Pfizer Inc. has a twelve month low of $23.58 and a twelve month high of $29.09.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. The firm had revenue of $15.03 billion for the quarter, compared to analysts’ expectations of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Research analysts expect that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th were issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.0%. The ex-dividend date was Friday, July 24th. Pfizer’s dividend payout ratio is 226.32%.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on PFE. Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday. Wall Street Zen upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a research report on Monday, July 6th. BMO Capital Markets cut their target price on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a research note on Monday, July 13th. Finally, Bank of America reduced their price target on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $28.28.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Strong quarterly results supported the move higher. Pfizer’s second-quarter earnings and revenue exceeded analyst expectations, while full-year 2026 EPS guidance remains $2.80–$3.00. The results suggest resilience despite comparisons with the prior year’s COVID-related performance. Pfizer Stock Surges to 52-Week Peak Following Strong Q2 Results and Major Legal Settlement
• Positive Sentiment: Depo-Provera litigation uncertainty has been reduced. Pfizer reached a confidential settlement covering more than 6,000 federal lawsuits alleging a connection between Depo-Provera and intracranial meningioma. Although the financial terms were not disclosed and Pfizer admitted no liability, the agreement removes a significant legal overhang. Pfizer Reaches Confidential Settlement in Depo-Provera Litigation
• Positive Sentiment: Investors are focusing on oncology growth. Padcev, pipeline programs such as PF-08634404 and potential label expansions are central to Pfizer’s effort to offset declining COVID product sales and build longer-term growth. Pfizer’s Oncology Growth Push
• Positive Sentiment: Higher EPS estimates and dividend appeal may be supporting demand. Erste Group Bank increased its FY2026 EPS estimate, while Pfizer’s relatively high dividend yield may attract income-oriented investors seeking defensive healthcare exposure. Pfizer FY2026 EPS Estimate Increased by Erste Group Bank
• Neutral Sentiment: Analysts remain moderately optimistic, but Pfizer has underperformed the S&P 500 over the past year, underscoring continuing concerns about growth and execution. Is Pfizer Stock Underperforming the S&P 500?
• Negative Sentiment: Unusual options activity included purchases of 147,173 put options, about 24% above average. This may reflect bearish positioning or hedging and signals that some traders remain cautious despite the recent rally.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.